DDInter1925 DDInter1016
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Vemurafenib {u} (Compound) resembles {v} (Compound) Etoricoxib
Vemurafenib {u} (Compound) treats {v} (Disease) skin cancer
Vemurafenib {u} (Compound) binds {v} (Gene) CYP3A4
Vemurafenib {u} (Compound) upregulates {v} (Gene) DHRS12
Vemurafenib {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Vemurafenib {u} (Compound) downregulates {v} (Gene) CLPP
Vemurafenib {u} (Compound) causes {v} (Side Effect) Eosinophilia
Vemurafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Vemurafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ambrisentan
Vemurafenib (Compound) resembles Etoricoxib (Compound)
Vemurafenib (Compound) treats skin cancer (Disease)
Vemurafenib (Compound) binds CYP3A4 (Gene)
Vemurafenib (Compound) upregulates DHRS12 (Gene)
Vemurafenib (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Vemurafenib (Compound) downregulates CLPP (Gene)
Vemurafenib (Compound) causes Eosinophilia (Side Effect)
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ambrisentan